As shown in Table 1, patients who used SGLT2 inhibitors performed younger age, higher BMI and HbA1c, shorter duration of diabetes and preserved kidney function, with the higher prevalence of dyslipidemia, cardiovascular disease, diabetic retinopathy and lower prevalence of hypertension, anemia and hyperuricemia. Here, SLC5A2 is linked to anemia.